Skip to main content

CNS Pharmaceuticals, Inc. (CNSP)

Sector
Healthcare
Industry
Biotechnology
Last price
$4.15
As of

Kresmion compiles this page from CNSP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

CNS Pharmaceuticals, Inc. (CNSP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-16.

As of . Source: SEC EDGAR filings for CNSP. Method and limitations.

COMPANY DOSSIER

See the full CNSP dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for CNSP on one page. Preview it with sample data, then open it live with a free account.

Preview the CNSP dossier

Active events for CNSP

  • mediumEarnings above estimates

    Q3-2026: Beat consensus by 12.9%, EPS $-0.24 vs $-0.2754 estimate

  • mediumEarnings below estimates

    Q2-2026: Missed consensus by 55.2%, EPS $-0.38 vs $-0.2448 estimate

  • mediumEarnings above estimates

    Q2-2025: Beat consensus by 34.4% - EPS $-6.42 vs $-9.792 estimate

  • mediumEarnings above estimates

    Beat consensus by 34.4% - EPS $-6.42 vs $-9.792 estimate

  • mediumEarnings above estimates

    Q3-2025: Beat consensus by 20.4% - EPS $-5.76 vs $-7.2369 estimate

FREE, NO ACCOUNT

Every event on CNSP, as it fires

You are seeing 5 of 7 events recorded on CNSP since 2026-05-29.

The five above landed across 4 days. The other 2 were recorded on those same days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter.

Recent SEC filings, CNSP

More data on CNSP

CNSP against its peers

CNSP's return on equity of -350.5% ranks in the 18th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricCNSPPeer medianPercentilen
Revenue FYn/a418189n/a18
Revenue YoYn/a-39.9%n/a5
Gross marginn/a20.4%n/a7
Operating marginn/a-631.0%n/a15
Net marginn/a-698.3%n/a16
Return on equity-350.5%-151.2%1819
1 year-48.3%-74.9%8320

Peers (22): LGVN, ACXP, BGMS, TCRT, CSCIF, CRIS, PCSA, JAGX, SNTI, XCUR, CDIO, KPRX, AIM, OSRH, SNGX, PULM, IMRN, NIKI, CANF, CNSY, RVPH, EVGN. Left out: ADAPY (no annual filing), ENVB (no annual filing), ADXN (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (CNSP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in CNSP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CNSP in the last 180 days.

Upstream: SEC EDGAR filings for CNSP

Kresmion, "CNS Pharmaceuticals, Inc. (CNSP) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/CNSP. Upstream data: SEC EDGAR filings for CNSP.

Link to this data (HTML):

<a href="https://kresmion.com/research/CNSP">CNS Pharmaceuticals, Inc. (CNSP) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow CNSP on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CNSP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the CNSP dossier
Share

The CNSP intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.